Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] R RESPIRATORY SYSTEM R03 DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES R03A ADRENERGICS, INHALANTS R03AL Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids R03AL03 Vilanterol and umeclidinium bromide D10533 Umeclidinium bromide and vilanterol <JP/US> USP drug classification [BR:br08302] Respiratory Tract/Pulmonary Agents Bronchodilator Combinations Umeclidinium/ Vilanterol D10533 Umeclidinium bromide and vilanterol Therapeutic category of drugs in Japan [BR:br08301] 2 Agents affecting individual organs 22 Respiratory organ agents 225 Bronchodilators 2259 Others D10533 Umeclidinium bromide and vilanterol Drug groups [BR:br08330] Cardiovascular agent DG01456 Adrenergic receptor agonist DG01455 beta-Adrenergic receptor agonist DG01453 beta3-Adrenergic receptor agonist D10533 Umeclidinium bromide and vilanterol Metabolizing enzyme substrate DG01644 CYP2D6 substrate D10533 Umeclidinium bromide and vilanterol DG01633 CYP3A/CYP3A4 substrate DG02913 CYP3A4 substrate D10533 Umeclidinium bromide and vilanterol New drug approvals in the USA [br08319.html] New molecular entities and new therapeutic biological products D10533 New drug approvals in Europe [br08329.html] European public assessment reports (EPAR) authorised medicine D10533 New drug approvals in Japan [br08318.html] Drugs with new active ingredients D10533 New drug approvals in the USA, Europe and Japan [br08328.html] Approval dates by FDA, EMA and PMDA D10533 Drug metabolizing enzymes and transporters [br08309.html] Drug metabolizing enzymes D10533
